Welcome to our dedicated page for Haoxi Health Technology SEC filings (Ticker: HAO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the numbers behind Haoxi Health Technology Limited’s growth in China’s healthcare advertising space? Whether you’re combing through the Haoxi Health Technology Limited annual report 10-K simplified to see how client concentration impacts revenue, or checking the Haoxi Health Technology Limited quarterly earnings report 10-Q filing for media-buy costs, the answers start here.
Stock Titan delivers every filing as soon as it hits EDGAR and translates dense disclosures into plain language. Our AI-powered summaries flag cash-flow swings, highlight regulatory risks and decode Haoxi Health Technology Limited 8-K material events explained within minutes. Need to stay ahead of executive moves? Monitor Haoxi Health Technology Limited insider trading Form 4 transactions and get Haoxi Health Technology Limited Form 4 insider transactions real-time without wading through raw PDFs. Key features include:
- Concise explanations of complex footnotes—understanding Haoxi Health Technology Limited SEC documents with AI
- Instant alerts on Haoxi Health Technology Limited executive stock transactions Form 4
- Side-by-side trend graphs for revenue, ad-production costs and segment margins
Each filing type unlocks different insights: the proxy statement reveals board pay (Haoxi Health Technology Limited proxy statement executive compensation), while 10-Qs track short-video campaign spend and 8-Ks capture new media partnerships. Our platform ties these documents back to real investor use cases—compare quarter-over-quarter ROAS, assess capital requirements, or spot patterns with Haoxi Health Technology Limited earnings report filing analysis. Complex filings made clear, in one place.
Haoxi Health Technology Limited filed a Form 6-K announcing that materials for an Extraordinary General Meeting of Shareholders are available. The filing attaches the Notice and Proxy Statement as Exhibit 99.1 and the Proxy Card as Exhibit 99.2.
The company notes it is a foreign private issuer and that the Notice is not subject to SEC review and comment. Shareholders are urged to read the Notice for important details about the meeting. Copies are available on the SEC’s website at www.sec.gov and on the company’s website at http://www.haoximedia.com/.
The company, its Board, and executive officers may be deemed participants in the proxy solicitation, with additional information about their interests described in the Notice.
Haoxi Health Technology Limited closed a Regulation S private placement to non‑U.S. persons, issuing 5,217,391 Class A ordinary shares at $0.23 per share for gross proceeds of $1.2 million. The transaction closed on October 22, 2025, and net proceeds will be used for working capital and general corporate purposes.
Following the closing, shares outstanding were 7,503,028 Class A and 690,800 Class B, each with a par value of $0.0025, as of the date of this report. The shares were issued in reliance on the Securities Act’s Regulation S exemption.
Haoxi Health Technology Limited (HAO) filed its annual report on Form 20-F. The Cayman holding company operates in China through its subsidiary, providing one-stop online marketing solutions, especially short video ads, mainly for healthcare clients. It also launched livestreaming agency services in April 2025, which have not generated revenue.
The company completed an IPO at $4.00 per share, including an over-allotment, for total gross proceeds of $11,040,000. A 25-for-1 share consolidation and share capital reorganization took effect on January 10, 2025, setting authorized capital at 300,000,000 Class A and 100,000,000 Class B shares, each with $0.0025 par value. An aggregate of 2,896,595 ordinary shares were outstanding as of June 30, 2025 (2,205,795 Class A; 690,800 Class B).
The report highlights PRC regulatory risks, including CSRC filing requirements for overseas offerings. The company completed CSRC filing for its IPO in 2023 and filed regarding a follow-on in 2024. No dividends have been paid; future earnings are intended for reinvestment. Auditor Wei, Wei & Co., LLP is PCAOB-inspected, addressing HFCA Act risks noted.
Haoxi Health Technology entered a securities purchase agreement to raise capital through a private placement. On October 13, 2025, the company agreed to sell 5,217,391 Class A ordinary shares for an aggregate purchase price of approximately $1.2 million to certain non‑U.S. investors under Regulation S. The company plans to use the proceeds for working capital and general corporate purposes.
The agreement includes customary representations and warranties and is subject to various conditions to closing, including the accuracy of the parties’ representations. The shares are being offered in a transaction exempt from U.S. registration. A form of the Securities Purchase Agreement was filed as an exhibit.
FAQ
What is the current stock price of Haoxi Health Technology (HAO)?
What is the market cap of Haoxi Health Technology (HAO)?
